相似文献
1
Functional and molecular imaging of localized and recurrent prostate cancer.
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1(Suppl 1):S48-59. doi: 10.1007/s00259-013-2419-6. Epub 2013 May 7.
2
Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
J Nucl Med. 2014 Feb;55(2):223-32. doi: 10.2967/jnumed.113.123018. Epub 2014 Jan 16.
3
Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging.
J Urol. 2017 Jan;197(1):129-134. doi: 10.1016/j.juro.2016.07.073. Epub 2016 Jul 20.
4
Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.
JAMA Oncol. 2017 Oct 1;3(10):1415-1422. doi: 10.1001/jamaoncol.2016.5840.
5
[Place of molecular imaging in the management of prostate cancer].
Cancer Radiother. 2021 Oct;25(6-7):663-666. doi: 10.1016/j.canrad.2021.07.032. Epub 2021 Aug 14.
6
Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse.
Abdom Radiol (NY). 2025 Feb;50(2):807-826. doi: 10.1007/s00261-024-04412-7. Epub 2024 Sep 10.
7
Clinical performance of Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):20-30. doi: 10.1007/s00259-017-3850-x. Epub 2017 Oct 14.
8
Whole-Body Integrated [Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
Mol Imaging Biol. 2020 Jun;22(3):788-796. doi: 10.1007/s11307-019-01424-4.
9
Recurrent prostate cancer: combined role for MRI and PSMA-PET in Ga-PSMA-11 PET/MRI.
Eur Radiol. 2024 Jul;34(7):4789-4800. doi: 10.1007/s00330-023-10442-4. Epub 2023 Dec 1.
10
Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging.
Curr Urol Rep. 2010 May;11(3):180-90. doi: 10.1007/s11934-010-0105-9.
引用本文的文献
1
The Role of Whole-Gland and Focal Cryotherapy in Recurrent Prostate Cancer.
Cancers (Basel). 2024 Sep 22;16(18):3225. doi: 10.3390/cancers16183225.
2
Surveillance one year post focal cryotherapy for clinically significant prostate cancer using mpMRI and PIRADS v2.1: An initial experience from a prospective phase II mandatory biopsy study.
Eur J Radiol Open. 2023 Oct 21;11:100529. doi: 10.1016/j.ejro.2023.100529. eCollection 2023 Dec.
3
Comparison of PSMA-based F-DCFPyL PET/CT and pelvic multiparametric MRI for lesion detection in the pelvis in patients with prostate cancer.
Am J Nucl Med Mol Imaging. 2022 Dec 15;12(6):166-179. eCollection 2022.
4
PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [Ga]Ga-NODAGA-AMBA and [Sc]Sc-NODAGA-AMBA.
Int J Mol Sci. 2022 Sep 2;23(17):10061. doi: 10.3390/ijms231710061.
5
Prostate MR Imaging for Posttreatment Evaluation and Recurrence.
Radiol Clin North Am. 2018 Mar;56(2):263-275. doi: 10.1016/j.rcl.2017.10.008. Epub 2017 Nov 27.
6
Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.
Top Magn Reson Imaging. 2016 Jun;25(3):139-47. doi: 10.1097/RMR.0000000000000088.
7
Technical challenges in 3 T magnetic resonance spectroscopic imaging of the prostate-A single-institution experience.
Quant Imaging Med Surg. 2014 Aug;4(4):251-8. doi: 10.3978/j.issn.2223-4292.2014.07.09.
8
Multiparametric MRI in prostate cancer management.
Nat Rev Clin Oncol. 2014 Jun;11(6):346-53. doi: 10.1038/nrclinonc.2014.69. Epub 2014 May 20.
9
Clinical and research applications of simultaneous positron emission tomography and MRI.
Br J Radiol. 2014 Jan;87(1033):20130464. doi: 10.1259/bjr.20130464. Epub 2013 Nov 14.
10
A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.
J Nucl Med. 2013 Dec;54(12):2132-8. doi: 10.2967/jnumed.113.121533. Epub 2013 Nov 6.
本文引用的文献
1
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.
Radiology. 2013 Jan;266(1):207-17. doi: 10.1148/radiol.12120281. Epub 2012 Nov 9.
2
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer.
BJU Int. 2012 Dec;110(11 Pt B):E783-8. doi: 10.1111/j.1464-410X.2012.11646.x. Epub 2012 Nov 6.
3
Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
AJR Am J Roentgenol. 2012 Nov;199(5):1114-20. doi: 10.2214/AJR.11.8351.
4
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.
Radiology. 2012 Nov;265(2):478-87. doi: 10.1148/radiol.12120041. Epub 2012 Sep 5.
5
The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis.
AJR Am J Roentgenol. 2012 Jul;199(1):103-10. doi: 10.2214/AJR.11.7634.
6
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.
J Nucl Med. 2012 Aug;53(8):1175-84. doi: 10.2967/jnumed.111.100883. Epub 2012 Jun 22.
7
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.
AJR Am J Roentgenol. 2012 Jun;198(6):1277-88. doi: 10.2214/AJR.12.8510.
8
Multiparametric MRI and prostate cancer diagnosis and risk stratification.
Curr Opin Urol. 2012 Jul;22(4):310-5. doi: 10.1097/MOU.0b013e32835481c2.
9
Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer.
J Magn Reson Imaging. 2012 Aug;36(2):430-7. doi: 10.1002/jmri.23672. Epub 2012 Apr 25.
10
Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations.
Magn Reson Med. 2013 Feb;69(2):553-62. doi: 10.1002/mrm.24277. Epub 2012 Apr 9.
Zotero 插件